Exploring the role of microbiota and inflammation in tic fluctuations

探索微生物群和炎症在抽动波动中的作用

• 批准号: 10431544
• 负责人: Marco Bortolato
• 金额: $ 24.36万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10431544
• 关键词: Acute; Adolescent; Affect; Animal Model; Animals; Anti-Inflammatory Agents; Archaea; Area; Bacteria; Behavior; Biological Process; Blood; Blood specimen; Brain; Child; Chronic; Clinical; Clinical Research; Communities; Corpus striatum structure; Development; Dietary Factors; Dose; Feces; Functional disorder; Funding; Future; Germ-Free; Gilles de la Tourette syndrome; Goals; Individual; Inflammation; Inflammatory; Inflammatory Response; Intestines; Lead; Leukocyte L1 Antigen Complex; Lifestyle-related condition; Link; Measures; Modification; Molecular; Mus; Participant; Pathogenesis; Patients; Peripheral; Pharmaceutical Preparations; Pharmacology; Probiotics; Problem Solving; Production; Role; Running; Safety; Sampling; Serious Adverse Event; Severities; Shapes; Source; Specimen; TNF gene; Testing; Thalamic structure; Therapeutic; Tic disorder; Time; Transplantation; Variant; Waxes; antagonist; associated symptom; base; behavioral response; beta-Defensins; cytokine; dietary; disability; experimental study; factor A; fecal transplantation; fungus; gastrointestinal system; gut microbiota; microbiota; mouse model; novel; psychiatric comorbidity; psychiatric symptom; rRNA Genes; relating to nervous system; stereotypy; translational impact; translational study; transplant model

ABSTRACT Chronic tic disorders (CTD), including Tourette’s disorder and persistent tic disorders, are a significant source of disability for children and adolescents, yet pharmacological therapies remain highly unsatisfactory due to serious adverse events. An ideal direction to develop safer treatments for CTD would be to target the same biological processes whereby tics spontaneously wax and wane over time; however, the mechanisms underlying these fluctuations remain poorly understood. A novel opportunity to solve this problem may come from recent evidence documenting that tic severity is influenced by the gut microbiota. Understanding whether changes in the composition of the gut microbiota may account for tic exacerbations - and through which molecular mechanisms - may lead to therapeutic breakthroughs in CTD; this issue, however, remains unexplored. The goal of the studies proposed in this R21 application is to explore whether and how variations in the gut microbiota contribute to tic exacerbations. The gut microbiota may influence tic severity through multiple mechanisms, including the synthesis of inflammatory cytokines. Ample correlational evidence points to tumor necrosis factor-α (TNF) as the inflammatory cytokine best associated with tic exacerbations. Thus, to test whether this cytokine increases tic severity, we evaluated its effects in a mouse model of CTD. These preliminary studies showed that low TNF doses that do not elicit sickness behavior significantly increase tic-like stereotypies in these mice. Based on these findings, we hypothesize that, in CTD patients, gut microbiota alterations lead to increased production of TNF or other inflammatory cytokines, which exacerbate tics. To test this hypothesis, the exploratory studies proposed in this R21 application will use a translational platform, combining clinical analyses in CTD patients and mechanistic experiments in mouse models. Specifically: - In Aim 1, we will assess the alterations of gut microbiota associated with CTD and test whether tic exacerbations are associated with alterations of the gut microbiota and inflammatory responses by testing fecal and blood samples from forty CTD patients and forty non-affected controls. - In Aim 2, we will test the causal link between gut microbiota alterations and tic exacerbations by transplanting fecal specimens from CTD-affected individuals into our mouse models of Tourette’s disorder; we will also test whether TNF or other inflammatory cytokines contribute to potential changes in tic severity. The translational studies proposed in this R21 application will be the first systematic analyses of the role of gut microbiota in tic fluctuations. If our hypothesis is verified, future R01-funded studies will test whether fecal material transplant from non-affected individuals and/or probiotic treatments can reduce tic severity. We will also study the downstream mechanisms whereby inflammation increases tic severity. Thus, our results may lead to the development of new, safer, mechanistically based treatments for CTD.

摘要